^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CART-BCMA/CS1

    i
    Other names: CART-BCMA/CS1
    Associations

    News

    Trials
    Company:
    UCLA Jonsson Comprehensive Cancer Center
    Drug class:
    BCMA-targeted CAR-T immunotherapy, CS-1-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    7ms
    CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Jonsson Comprehensive Cancer Center | N=30 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • IO biomarker
    |
    CD38 positive
    |
    cyclophosphamide • fludarabine IV • CART-BCMA/CS1
    11ms
    CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Dec 2027 --> Mar 2028 | Initiation date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2026 --> Mar 2027
    Trial completion date • Trial initiation date • Trial primary completion date • IO biomarker
    |
    CD38 positive
    |
    cyclophosphamide • fludarabine IV • CART-BCMA/CS1
    over1year
    CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P1 trial • IO biomarker
    |
    CD38 positive
    |
    cyclophosphamide • fludarabine IV • CART-BCMA/CS1